Scynexis Inc (SCYX) Stock Analysis

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

• Price: $0.70
• Market Cap: $29.80M
• EPS: $-0.51
• 52-Week High: $1.31
• 52-Week Low: $0.56

Market Sentiment

Scynexis Inc currently has a Bullish sentiment score of 0.43.

About Scynexis Inc

Scynexis Inc. is a biotechnology firm headquartered in Jersey City, New Jersey, specializing in innovative therapies for the treatment of invasive fungal infections, with a particular focus on serious yeast infections. The company’s lead product candidate, BREXAFEMME®, is the first oral therapeutic specifically indicated for the treatment of vulvovaginal candidiasis, representing a significant advancement in antifungal therapy. With a robust pipeline and a commitment to addressing unmet medic...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Scynexis Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does SCYX pay dividends?

Scynexis Inc (SCYX) does not currently pay a regular dividend.

What is SCYX's market cap?

Scynexis Inc (SCYX) has a market capitalization of $29.80M with a current stock price of $0.70.